Replies to post #2701 on Entremed (ENMD)

[georgejjl]

Correction the Phase 1b trials are currently still enrolling

"Clinical Trials Enrolling as of July 28, 2005

Product Location Principal
Investigator Indication Phase Contact
Panzem® NCD
Press Release University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison, WI Dr. George Wilding Advanced Cancer Ib Cancer Connect: Patient and Physician
Resource:
1- 800-622-8922 or [phone]

UWCCC
600 Highland Avenue, K4/6 Madison,
WI 53792-6164
Indiana University Cancer Center, Indianapolis, IN Dr. Christopher J. Sweeney http://iucc.iu.edu "

Good luck and God bless,

George

[docaaron1]

As to Allergan, Burns said it was a mutual decision. They did not wish to pursue it and we wanted to focus on cancer and inflammation. I really don’t think it was a 50/50 decision to end the project. I have pigeonholed Panzem to work best as microtubule disruptor-HIF inhibitor in a hypoxic environment. My gut feeling is that it did not work well on the non-hypoxic leaky vessels of AMD. George are there any papers out there that has 2me2 working on AMD? I don’t mind being wrong.

Aaron